ArticleThe Journal of antimicrobial chemotherapy2025
In vitro evaluation of olorofim and antifungal combinations against Aspergillus and Candida species.
Article in The Journal of antimicrobial chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Olorofim in combination with azole antifungals: results from the Phase 2 salvage therapy study.The Journal of antimicrobial chemotherapy · 2026Trial
- In Vitro Evaluation of Olorofim and Amphotericin B Combination Therapy AgainstJournal of fungi (Basel, Switzerland) · 2026Article
- Comment on: Antagonistic in vitro interaction between olorofim and voriconazole against Aspergillus fumigatus.The Journal of antimicrobial chemotherapy · 2026Article
- Article
- Antagonistic interaction between posaconazole and olorofim in a murine model of invasive pulmonary aspergillosis.The Journal of antimicrobial chemotherapy · 2025Article
- Invasive Fungal Disease in Allogeneic Hematopoietic Cell Transplantation: New Risk Factors and New Therapeutic Options in a Changing World.Transplant infectious disease : an official journal of the Transplantation SocietyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesAspergillus and Candida spp. are important causes of systemic fungal infections. Although various therapies are available, resistance to current antifungal treatments, particularly azoles, is increasing. Combinations of antifungals can be used to treat infections with resistant pathogens. In a recent in vitro study, antagonism was reported in a single A. fumigatus isolate between olorofim and voriconazole. Available clinical data are limited but do not reflect this phenomenon. The in vitro interactions of olorofim with current antifungal agents (voriconazole, posaconazole, isavuconazole, fluconazole, amphotericin B, terbinafine and caspofungin) were evaluated against various Aspergillus and three Candida species.
methodsIn vitro interactions were evaluated by the EUCAST microdilution broth technique modified for checkerboard assay.
resultsOlorofim demonstrated different interaction patterns when tested in combination with various classes of antifungal. Unidirectional antagonism was seen between olorofim and the mould-active azoles with the strongest effect seen in A. niger: azole MIC values were unaffected but olorofim MIC values increased, although remained within wild-type distributions. Olorofim antagonized amphotericin B activity in the single A. niger strain tested. There was indifference between olorofim and fluconazole, terbinafine and caspofungin for all isolates. Finally, olorofim showed indifference with fluconazole or voriconazole against three Candida species.
conclusionsMould-active azoles antagonize olorofim activity against Aspergillus spp. combination MICs remain within wild-type distributions for Aspergillus spp., other than for A. niger. In addition, olorofim does not affect the anti-Candida effect of fluconazole and could be co-dosed where necessary without loss of the effect of the azole against the yeast.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.